SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
P. Sarafidis, C. J. Ferro, E. Morales, A. Ortiz, J. Malyszko, et al.. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2020, 35 (10), pp.1825. ⟨10.1093/ndt/gfz137⟩. ⟨inserm-03261177⟩